Tag: YESAFILI
Biocon reports 30% revenue increase and ₹660 crore net profit in...
Biocon's Q1FY25 performance sees 117% EBITDA growth and ₹660 crore net profit, powered by strategic partnerships and biosimilar success
Biocon Biologics receives MHRA, UK approval for YESAFILI, a biosimilar of...
In September, YESAFILI®, received marketing authorization approval from the European Commission (EC) for the European Union (EU)
Biocon Biologics announces positive CHMP opinion for its biosimilar to treat...
The CHMP positive opinion will be considered by the European Commission whose decision on the approval is expected by the end of September 2023